|Articles|March 6, 2006
entimo AG Ushers in New Era of Clinical Data Repository-Based Data Analysis and Reporting Environments
entimICER DARE dramatically improves how pharmaceutical companies can manage, analyze, and report on clinical data.
Advertisement
Paris – 06/03/2006 – entimo AG, a leading company providing manufacturers of the pharmaceutical and crop science industries with high quality e-business Research & Development (eR&D) products and solutions, as well as custom IT solutions for the regulatory authorities, today announced the general availability of its flagship product entimICE DARE to all customers worldwide.
entimICE DARE is a comprehensive and flexible product that ensures seamless operation across different stages of clinical development by enabling the user to view, manage, analyze and report data across clinical applications, and across projects or trials, within the same environment, and in a regulatory compliant manner. entimICE DARE is designed to meet the needs of clinical research and development personnel - such as clinical monitors, clinical research associates, biostatisticians, programmers, etc. - involved in the integration, management, analysis and reporting of clinical trial data. Now pharmaceutical companies can have a customizable repository based data analysis and reporting environment that is cost effective, easy to implement, and tailored to their business - all without having to write a single line of code.
"entimICE DARE is filling the gap of traceability between CDMS and submission in a customizable manner" said Juergen Spieler, chief executive officer of entimo AG. "With this release, entimo AG raises the bar for clinical data repository based solutions for managing, analyzing and reporting of clinical data, delivering pharmaceutical companies unprecedented value. The enhanced functionality that our entimICE DARE solution provides enables pharmaceutical companies of all sizes to meet the increasing demands of regulatory compliance, such as GxP and CFR Part 11, head-on, while providing them the flexibility to customize their solution based on their unique business requirements."
entimICE DARE provides:
General features
- Uniform and customizable environment for clinical data building, analysis and reporting (cross trial and individual level)
- Global metadata repository
- Integrating SAS
- Easy to use graphical user interface
Regulatory compliance
- 21 CFR part 11
- GCP
Secure access
- Secure login-ins
- Allocation of users to roles (general or e.g. only in a specific study)
- Role based access right definition
- User and role administration by privileged users
- Allocation of electronic signature for actions
Structure definition
- Structure definition and administration features (e.g. different study and project types)
Traceability
- Audit trail for objects (according to structures, access rights, contents)
- History of objects
- Versioning of objects
- Action log (executed user actions)
- Program execution trace (parameters and their used values, input objects, output objects)
- Electronic signature
Workflow
- Definable with structure administration feature (e.g. status values based action execution)
- Test and production environments
- Metadata management
- Metadata for all data objects
- Data can be allocated to metadata
- Check, check-in, check-out of data based on related metadata
- Regimented and audited changes of metadata, follow-up changes of depending data
Data management
- Import/export of different data object types (SAS, Oracle.)
- Browse and edit features
- Transformation, reporting, analyzing using company standard and / or user programs
Statistical analysis and program management and execution
- Program creation and maintenance with the help of special editors
- Optional definition and description of program parameters
- Execution in dialog and/or batch with parameter setting
- Program rerun support
For more information, please visit the company's website at www.entimo.com .
Articles in this issue
over 19 years ago
Article
Biophage Pharma Signs an Exclusive Licensing Agreement with Melisa Diagnostics Ltd.over 19 years ago
Article
Cognitive Drug Research Signs Development Agreement With Pharma Services Networkover 19 years ago
Article
Phase Forward Shows Strong Presence at DIA 18th Annual EuroMeeting Conferenceover 19 years ago
Article
Medidata Solutions to Provide Clinical Data Management Expertise at 18th Annual DIA EuroMeetingover 19 years ago
Article
PRA International Names Dr. Cynthia Kirk Vice President of Global Regulatory AffairsNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
2
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
3
Latest NIMBLE Study Results Highlight Progress in gMG Research
4
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
5